吡格列酮治疗顽固性高血压病合并胰岛素抵抗患者的疗效观察

Clinical Observation of Pioglitazone in the Treatment of Resistant Hypertension with Insuline Resistance

目的观察吡格列酮对顽固性高血压并胰岛素抵抗患者的疗效。方法选择46例顽固性高血压病合并胰岛素抵抗患者,随机分为两组,治疗组:每日加口服吡格列酮15mg,1次/d,共8周;对照组:原用的降压药不变,原生活方式不变。所有对象均于加用药前和加用药8周末检测血压、空腹血浆葡萄糖(FBG)、血清胰岛素(FINS),并作比较分析。结果治疗组患者的SBP、DBP、FPG、FINS和胰岛素抵抗指数(HOMA-IR)值,较治疗前均有显著性下降(P<0.01)。结论吡格列酮治疗顽固性高血压病合并胰岛素抵抗患者,不仅可使其空腹血糖明显下降,而且还具有降低患者血压和血清胰岛素水平,改善其胰岛素抵抗作用。

Objective To observe the clinical curative effect of pioglitazone in the treatment of resistant hypertension with insuline resistance. Methods A total of 46 patients with resistant hypertension with insuline resistance were randomly divided into control group and treatment group. All the patients were treated with the same three sorts of hypotensive drug. The patients in the control group were treated with the invariant treatment and the patients of the treatment group were treated with 15mg pioglitazone everyday on the basis of the control group. The patients of two groups were both treated for two months. All the patients were detected blood pressure, FBG and FINS before and after the treatment. Results After two months of the treatment, the SBP, DBP, FPG, FINS and the insulin resistance index（HOMA-IR）were declined obviously in the treat groups（P〈0.01）. Conclusion Pioglitazone treatment of resistant hypertension complicated with insulin resistance, not only to decreased fasting blood glucose, but also can reduce blood pressure and serum insulin levels, improve insulin resistance.